JP2015531407A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531407A5
JP2015531407A5 JP2015536826A JP2015536826A JP2015531407A5 JP 2015531407 A5 JP2015531407 A5 JP 2015531407A5 JP 2015536826 A JP2015536826 A JP 2015536826A JP 2015536826 A JP2015536826 A JP 2015536826A JP 2015531407 A5 JP2015531407 A5 JP 2015531407A5
Authority
JP
Japan
Prior art keywords
protein
cell
modified
ompt1
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015536826A
Other languages
English (en)
Japanese (ja)
Other versions
JP6421122B2 (ja
JP2015531407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/063804 external-priority patent/WO2014058830A1/en
Publication of JP2015531407A publication Critical patent/JP2015531407A/ja
Publication of JP2015531407A5 publication Critical patent/JP2015531407A5/ja
Application granted granted Critical
Publication of JP6421122B2 publication Critical patent/JP6421122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015536826A 2012-10-12 2013-10-08 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 Active JP6421122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
US61/713,245 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017229231A Division JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Publications (3)

Publication Number Publication Date
JP2015531407A JP2015531407A (ja) 2015-11-02
JP2015531407A5 true JP2015531407A5 (https=) 2016-11-24
JP6421122B2 JP6421122B2 (ja) 2018-11-07

Family

ID=49447839

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015536826A Active JP6421122B2 (ja) 2012-10-12 2013-10-08 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2017229231A Withdrawn JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2020173282A Withdrawn JP2021003134A (ja) 2012-10-12 2020-10-14 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017229231A Withdrawn JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2020173282A Withdrawn JP2021003134A (ja) 2012-10-12 2020-10-14 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Country Status (14)

Country Link
US (3) US9650621B2 (https=)
EP (1) EP2906592B1 (https=)
JP (3) JP6421122B2 (https=)
KR (1) KR102018863B1 (https=)
CN (1) CN104837863B (https=)
AU (1) AU2013329464C1 (https=)
CA (1) CA2887355C (https=)
DK (1) DK2906592T3 (https=)
ES (1) ES2694683T3 (https=)
HU (1) HUE041721T2 (https=)
IL (1) IL238095B (https=)
PL (1) PL2906592T3 (https=)
SG (1) SG11201502875VA (https=)
WO (1) WO2014058830A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
CA2909516C (en) * 2013-04-19 2023-03-07 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
EP3882343A3 (en) * 2016-01-13 2021-12-08 New England Biolabs, Inc. Thermostable variants of t7 rna polymerase
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
WO2020205584A1 (en) 2019-04-02 2020-10-08 Vaxcyte, Inc. Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス, インコーポレイテッド Il-2コンジュゲートおよび抗egfr抗体を用いる免疫腫瘍学併用療法
CA3192331A1 (en) 2020-09-14 2022-03-17 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用il-2綴合物之癌症療法
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100445394C (zh) * 1999-03-04 2008-12-24 阿斯比奥制药株式会社 控制OmpT蛋白酶切割的方法
DE60226411D1 (de) 2001-01-25 2008-06-19 Anthony C Forster Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
ATE445699T1 (de) 2002-08-19 2009-10-15 Univ Leland Stanford Junior Verbesserte verfahren zur in-vitro- proteinsynthese
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
AU2004276687B2 (en) * 2003-09-30 2011-07-14 Asubio Pharma Co., Ltd. Method of cleaving polypeptide by using OmpT protease mutant
WO2006082059A1 (en) * 2005-02-02 2006-08-10 Universität Bayreuth Esterases for monitoring protein biosynthesis in vitro
US8367588B2 (en) 2005-10-12 2013-02-05 The Scripps Research Institute Selective posttranslational modification of phage-displayed polypeptides
KR20080113226A (ko) 2006-03-16 2008-12-29 더 스크립스 리서치 인스티튜트 비천연 아미노산 페닐셀레노시스테인을 함유하는 단백질의 유전자적으로 프로그램된 발현
CN102348807B (zh) 2009-01-12 2015-04-15 苏特罗生物制药公司 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Similar Documents

Publication Publication Date Title
JP2015531407A5 (https=)
KR102018863B1 (ko) 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화
JP7246100B2 (ja) 新規融合タンパク質の調製およびそのタンパク質合成の向上における使用
JP2017513479A5 (https=)
JP6681625B2 (ja) タンパク質の発現方法
JP2004532033A5 (https=)
US20160251636A1 (en) New methods to produce active tert
EP2914282A1 (en) Recombinant clostridium botulinum neurotoxins
JP2020529221A5 (https=)
JPWO2020027010A5 (https=)
Connor et al. Enzymatic N-terminal addition of noncanonical amino acids to peptides and proteins
JP3957630B2 (ja) 組換えヒト副甲状腺ホルモンを生産する形質転換酵母及び該ホルモンの生産方法
Guo et al. High level soluble production of functional ribonuclease inhibitor in Escherichia coli by fusing it to soluble partners
CN110257347B (zh) 硫氧还蛋白突变体、其制备方法及其在重组融合蛋白生产中的应用
Akaji et al. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
CN104387473A (zh) 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP
CN101886068B (zh) 一种固相化sumo化系统及固相化去sumo化系统
CN106701813A (zh) 表达载体及其构建方法与应用
AU2016327453A1 (en) Generation of peptides
TW200531978A (en) Removal of n-terminal methionine from proteins by engineered methionine aminopeptidase
AU2020391003B2 (en) Polypeptide tag and application thereof in in vitro protein synthesis
TWI591177B (zh) 一種胰高血糖素胜肽-2(glp-2)類似物的製備方法
US10988751B2 (en) Diphosphomevalonate decarboxylase variant and method for manufacturing olefin compound using same
KR100407792B1 (ko) 인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
Na et al. Expression and purification of ubiquitin-specific protease (UBP1) of Saccharomyces cerevisiae in recombinant Escherichia coli